Monday, May 6, 2024
ADVT 
International

Health panel expands lung cancer screening for more smokers

Darpan News Desk The Canadian Press, 09 Mar, 2021 09:32 PM
  • Health panel expands lung cancer screening for more smokers

More Americans now qualify for yearly scans to detect lung cancer, according to guidelines released Tuesday that may help more Black smokers and women get screened.

Lung cancer is the nation’s top cancer killer, causing more than 135,000 deaths each year. Smoking is the chief cause and quitting the best protection.

Usually, lung cancer is diagnosed too late for a good chance at survival. But some Americans who are at especially high risk get an annual low-dose CT scan, a type of X-ray, to improve those odds.

Who’s eligible? The U.S. Preventive Services Task Force said anyone between ages 50 and 80 who has smoked at least 20 “pack-years” and either still smokes or quit within the last 15 years. A “pack-year” means smoking a pack of cigarettes a day for a year or an equivalent amount. So someone could qualify by going through a pack a day for 20 years or two packs a day for 10 years.

Since 2013, the scans have been recommended for heavier smokers -- 30 pack-years -- and those a little older, starting at age 55. The task force updated the guidelines, published Tuesday in the Journal of the American Medical Association, after newer research showed lighter, younger smokers benefit, too. About 15 million people are estimated to meet the new criteria, nearly double the prior number.

The task force recommendation means insurers must offer the screening without a copay to people who meet the criteria.

The changes “mean more Black people and women are now eligible for lung cancer screening, which is a step in the right direction,” Dr. John B. Wong, a task force member at Tufts Medical Center, said in a statement.

The panel said African Americans and women tend to be less heavy smokers and may not have met the earlier screening threshold despite being at risk for lung cancer.

In an editorial in JAMA Surgery, cancer specialists welcomed the changes.

But "unfortunately, lowering the age and pack-year requirements alone does not guarantee increased equity in lung cancer screening,” wrote Dr. Yolonda Colson and colleagues at Massachusetts General Hospital.

Her team noted “formidable” barriers including poor access to health care and even doctors not familiar enough with the screening to identify good candidates and help them decide.

One recent study found just 14% of people eligible for lung cancer screening under the prior guidelines had actually gotten it. In contrast, 60% to 80% of people eligible for breast, colon or cervical cancer screening get checked.

People offered lung cancer screenings also must consider the risks of invasive testing to tell if any abnormality spotted by the scan really is a tumour. Lung biopsies occasionally cause serious, even fatal, complications.

MORE International ARTICLES

Trump formally lets Canadian aluminum off hook

Trump formally lets Canadian aluminum off hook
The U.S. president formally signed a proclamation today exempting Canadian aluminum exports from punitive Section 232 tariffs.

Trump formally lets Canadian aluminum off hook

Prince Harry says ignorance no excuse for unconscious bias

Prince Harry says ignorance no excuse for unconscious bias
Harry talked about racial inequality and social justice in a video discussion with the Black Lives Matter activist Patrick Hutchinson as part of the GQ Heroes Conference, which is being broadcast this week.

Prince Harry says ignorance no excuse for unconscious bias

Halloween goes on at the White House with a few twists

Halloween goes on at the White House with a few twists
In years past, the president and first lady personally handed out candy to the costume-clad kids. This year, the treats were provided separately as participants walked along a path on the South Lawn.

Halloween goes on at the White House with a few twists

AstraZeneca resuming US testing of COVID-19 vaccine

AstraZeneca resuming US testing of COVID-19 vaccine
The AstraZenca vaccine, developed with Oxford University, is one of several coronavirus vaccine candidates in final-stage testing around the world.

AstraZeneca resuming US testing of COVID-19 vaccine

FDA approves first COVID-19 drug: antiviral remdesivir

FDA approves first COVID-19 drug: antiviral remdesivir
The drug, which California-based Gilead Sciences Inc. is calling Veklury, cut the time to recovery by five days — from 15 days to 10 on average — in a large study led by the U.S. National Institutes of Health.

FDA approves first COVID-19 drug: antiviral remdesivir

Here we go again: Trump, Biden reprise debate duel

Here we go again: Trump, Biden reprise debate duel
Instead, they're bracing for another show of vintage Trump, one in which he'll seek to be heard even in spite of his muted microphone.

Here we go again: Trump, Biden reprise debate duel